US 12,187,793 B2
Single-domain antibody binding to the G protein alpha
Thomas Fabien Michel Roux, Nîmes (FR); Elodie Julie Dupuis, Caissargues (FR); Eric Jacques Christian Trinquet, Pont-Saint-Esprit (FR); Mélanie Da Silva, Saint-Macoux (FR); Camille S. Mailhac, Marseilles (FR); Patrick J M Chames, Marseilles (FR); Daniel Baty, Marseilles (FR); Julien Jean-Marius Soule, Montpellier (FR); Philippe Rondard, Saint-Gély-du-Fesc (FR); and Jean-Philippe R. Pin, Montpellier (FR)
Assigned to CISCIO BIOASSAYS, Codolet (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR)
Appl. No. 17/263,050
Filed by CISBIO BIOASSAYS, Codolet (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR)
PCT Filed Jul. 26, 2019, PCT No. PCT/FR2019/051858
§ 371(c)(1), (2) Date Jan. 25, 2021,
PCT Pub. No. WO2020/021213, PCT Pub. Date Jan. 30, 2020.
Claims priority of application No. 1857026 (FR), filed on Jul. 27, 2018.
Prior Publication US 2021/0309739 A1, Oct. 7, 2021
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/28 (2013.01) [C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01)] 11 Claims
 
1. A single-domain antibody (sdAb) which binds to G protein alpha, comprising an amino acid sequence consisting of 3 CDR regions (CDR1 to CDR3) and 4 hinge regions (FR1 to FR4) according to the following formula (I):
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4  (I)
said antibody having a dissociation constant (Kd) for the full G protein alpha, measured in Fluorescence Resonance Energy Transfer (FRET), of less than 100 nM, and wherein:
CDR1 comprises the amino acid sequence of SEQ ID NO: 1, CDR2 comprises the amino acid sequence of SEQ ID NO: 2 and CDR3 comprises the amino acid sequence of SEQ ID NO: 3;
CDR1 comprises the amino acid sequence of SEQ ID NO: 9, CDR2 comprises the amino acid sequence of SEQ ID NO: 10 and CDR3 comprises the amino acid sequence of SEQ ID NO: 11;
CDR1 comprises the amino acid sequence of SEQ ID NO: 17, CDR2 comprises the amino acid sequence of SEQ ID NO: 18 and CDR3 comprises the amino acid sequence of SEQ ID NO: 19;
CDR1 comprises the amino acid sequence of SEQ ID NO: 25, CDR2 comprises the amino acid sequence of SEQ ID NO: 26 and CDR3 comprises the amino acid sequence of SEQ ID NO: 27;
CDR1 comprises the amino acid sequence of SEQ ID NO: 33, CDR2 comprises the amino acid sequence of SEQ ID NO: 34 and CDR3 comprises the amino acid sequence of SEQ ID NO: 35;
CDR1 comprises the amino acid sequence of SEQ ID NO: 41, CDR2 comprises the amino acid sequence of SEQ ID NO: 42 and CDR3 comprises the amino acid sequence of SEQ ID NO: 43;
CDR1 comprises the amino acid sequence of SEQ ID NO: 49, CDR2 comprises the amino acid sequence of SEQ ID NO: 50 and CDR3 comprises the amino acid sequence of SEQ ID NO: 51;
CDR1 comprises the amino acid sequence of SEQ ID NO: 57, CDR2 comprises the amino acid sequence of SEQ ID NO: 58 and CDR3 comprises the amino acid sequence of SEQ ID NO: 59; or
CDR1 comprises the amino acid sequence of SEQ ID NO: 65, CDR2 comprises the amino acid sequence of SEQ ID NO: 66 and CDR3 comprises the amino acid sequence of SEQ ID NO: 67.